We showed that targeting TACC3 through knockdown or treatment with TACC3 inhibitor KHS101 in NSCLC cells that are resistant to TKI treatment resulted in partial resensitizing of TKI-resistant NSCLC cells to the TKI erlotinib. The gene discussed is TACC3; the disease is non-small cell lung carcinoma.